774
0.00%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ADR120S
Its shares trade on Tokyo Stock Exchange under the ticker 3750.T. It has been listed since 1 October 2004. In the fiscal year to 31 March 2026, it reported revenue of ¥51.0m and a net loss of ¥396.9m. At that date it held total assets of ¥368.1m and shareholders' equity of ¥22.0m.
Cytori Cell Research Institute, Inc. operates as a holding company which provides financial and marketing relates services. The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2004-10-01. The firm operates through two segments. The Real Asset segment is engaged in the purchase and sales of real estate and investment of real estate business related projects, as well as development, renovation and opening of hotels, and operation of hotels. The Medical segment is engaged in the investment of regenerative medicine business centered on cell therapy services, as well as sales of medical equipment and consumables. The main products include Celusion centrifuge and the Celusion cell therapy kit.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Real Estate
- Industry
- Real Estate Management & Development
- Listed since
- 1 Oct 2004
- Employees
- 64
- Website
- cytori.co.jp ↗
Leadership
Pay as last reported
- Mr. Yoshihiro HoshinoChairman of the Board, President, Representative Director, since 2018
- Mr. Yasushiro ShirahamaChairman of Subsidiary, Director, since 2020
- Mr. Tsuyoshi FujimuraDirector of Business Planning, Director, since 2023
- Mr. Akihiro AzumaDirector
- Mr. Hiroshi WakagiDirector
- Mr. Yasutaka HayashidaIndependent Director
- Mr. Hiroki KobayashiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ADR120S Inc operates in the Real Estate sector with a focus on the Real Asset segment in Chiyoda-ku, Tokyo-To.
- The company has a clear product lineup including Celusion centrifuge and Celusion cell therapy kit for the Medical segment.
- ADR120S Inc has been publicly traded since IPO on October 2004, providing market transparency.
Weaknesses
- ADR120S Inc is limited to two business segments, Real Asset and Medical, which may restrict diversification.
- The company's headquarters in Chiyoda-ku, Tokyo-To, may limit its operational reach to specific geographic markets.
- With only 64 employees, ADR120S Inc has a small workforce for its business scope.
Opportunities
- The Real Asset segment can expand into hotel development and renovation projects in Chiyoda-ku.
- The Medical segment's focus on regenerative medicine could leverage the Celusion cell therapy kit for market growth.
- The company's IPO listing since 2004 provides a foundation for future capital raising.
Threats
- The Real Estate industry faces competition from other firms in Chiyoda-ku, Tokyo-To.
- The Medical segment's reliance on cell therapy services may face regulatory challenges in Japan.
- The company's small employee count of 64 may hinder its ability to respond to market changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.